![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61P 3/00 | (2006.01) |
A61P 3/12 | (2006.01) | ||
C07K 14/575 | (2006.01) | ||
A61K 38/00 | (2006.01) |
(11) | Number of the document | 2968443 |
(13) | Kind of document | T |
(96) | European patent application number | 14763104.8 |
Date of filing the European patent application | 2014-03-17 | |
(97) | Date of publication of the European application | 2016-01-20 |
(45) | Date of publication and mention of the grant of the patent | 2021-09-29 |
(46) | Date of publication of the claims translation | 2021-12-10 |
(86) | Number | PCT/US2014/030352 |
Date | 2014-03-17 |
(87) | Number | WO 2014/145561 |
Date | 2014-09-18 |
(30) | Number | Date | Country code |
201361800048 P | 2013-03-15 | US | |
201361800284 P | 2013-03-15 | US |
(72) |
SMYTHE, Mark Leslie , AU
BOURNE, Gregory Thomas , AU
VINK, Simone , AU
FREDERICK, Brian T. , US
MADALA, Praveen , AU
TOFTENG SHELTON, Anne Pernille , DK
FOG, Jacob Ulrik , DK
|
(73) |
Protagonist Therapeutics, Inc. ,
7707 Gateway Boulevard, Suite 140, Newark, CA 94560-1160,
US
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Hepcidino analogai ir jų naudojimas |
HEPCIDIN ANALOGUES AND USES THEREOF |
Payment date | Validity (years) | Amount | |
2025-02-18 | 12 | 289.00 EUR |
2026-03-17 |